Investors are weighing the differences in cost and performance between the First Trust NYSE Arca Biotechnology ETF (FBT) and the iShares Biotechnology ETF (IBB).
Choosing between these two funds involves balancing the desire for aggressive growth against the need for diversification. Because biotech stocks are volatile, the structure of the ETF can significantly impact an investor's risk exposure.
The First Trust NYSE Arca Biotechnology ETF has demonstrated strong recent momentum, posting a one-year total return of 53.2% [1]. This growth comes with a lean cost structure, as the fund maintains an expense ratio of 11 basis points [2]. FBT was launched on June 19, 2006 [4], and it trades on the NYSE Arca exchange.
However, FBT carries a higher level of concentration risk than some of its peers. The fund holds only 30 stocks [3], a narrow selection that can amplify gains during bull markets but increase losses if a few key holdings fail.
In contrast, the iShares Biotechnology ETF offers a longer track record in the U.S. market. IBB launched on Feb. 5, 2001 [5], and trades on the NASDAQ. While the dossier does not provide a specific one-year return for IBB, its longer history provides a broader benchmark for how biotech assets perform across different market cycles.
Analysts said that the choice between the two depends on an investor's specific goals. Those seeking a more concentrated bet on a smaller group of companies may prefer the structure of FBT. Those prioritizing a legacy fund with a longer operational history may lean toward IBB.
“FBT posted a one-year total return of 53.2%”
The performance gap between these ETFs highlights the risk-reward profile of concentrated versus diversified portfolios. FBT's high returns and low expense ratio make it attractive for growth-oriented investors, but its limited number of holdings means it lacks the safety net of a broader index. Investors must decide if the potential for outsized gains outweighs the risk of a few underperforming stocks dragging down the entire fund.
